Mesenchymal Stem Cells as Therapeutics

被引：592

作者：

Parekkadan, Biju ^{[1
,2
]}

Milwid, Jack M. ^{[1
,2
,3
]}

机构：

[1] Massachusetts Gen Hosp, Ctr Engn Med & Surg Serv, Shriners Hosp Children, Boston, MA 02114 USA

[2] Harvard Univ, Sch Med, Boston, MA 02114 USA

[3] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA

来源：

ANNUAL REVIEW OF BIOMEDICAL ENGINEERING, VOL 12 | 2010年 / 12卷

关键词：

mesenchymal stem cell; immunotherapy; clinical trials; paracrine; extracorporeal bioreactor; conditioned medium; HUMAN BONE-MARROW; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; VERSUS-HOST-DISEASE; ACUTE-RENAL-FAILURE; LONG-TERM CULTURE; STROMAL CELLS; IN-VITRO; PROGENITOR CELLS; LYMPHOCYTE-PROLIFERATION; UMBILICAL-CORD;

D O I：

10.1146/annurev-bioeng-070909-105309

中图分类号：

R318 [生物医学工程];

学科分类号：

0831 ;

摘要：

Mesenchymal stem cells (MSCs) are multipotent cells that are being clinically explored as a new therapeutic for treating a variety of immune-mediated diseases. First heralded as a regenerative therapy for skeletal tissue repair, MSCs have recently been shown to modulate endogenous tissue and immune cells. Preclinical studies of the mechanism of action suggest that the therapeutic effects afforded by MSC transplantation are short-lived and related to dynamic, paracrine interactions between MSCs and host cells. Therefore, representations of MSCs as drug-loaded particles may allow for pharmacokinetic models to predict the therapeutic activity of MSC transplants as a function of drug delivery mode. By integrating principles of MSC biology, therapy, and engineering, the field is armed to usher in the next generation of stern cell therapeutics.

引用

页码：87 / 117

页数：31

共 186 条

[1] Immunomodulation by mesenchymal stem cells - A potential therapeutic strategy for type 1 diabetes [J].